Alprazolam Augmentation of the Antipsychotic Effects of Fluphenazine in Schizophrenic Patients

Preliminary Results

Owen M. Wolkowitz, Alan Breier, Allen Doran, John Kelsoe, Peter Lucas, Steven M. Paul, David Pickar

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Alprazolam was added, under double-blind conditions, to stable fluphenazine hydrochloride regimens in 12 symptomatic, chronically ill inpatients with schizophrenia. The addition of alprazolam was associated with significant, albeit modest, reductions in global psychosis, thought disorder, and paranoia ratings, with a return to pretreatment levels on discontinuation of alprazolam treatment. Improvement in "negative symptoms" such as emotional withdrawal paralleled the changes in "positive symptoms" but did not, in itself, reach statistical significance. There were no significant changes in group mean plasma levels of homovanillic acid or 3-methoxy-4-hydroxyphenylglycol during alprazolam treatment, although group mean serum cortisol levels were significantly decreased by alprazolam treatment. Patients who responded favorably to alprazolam treatment were significantly more psychotic or anxious before treatment, were older, showed significant alprazolam-associated reductions in plasma levels of homovanillic acid, and had significantly more prominent prefrontal cortex atrophy on computed tomographic scans than patients in whom alprazolam was without therapeutic effect. These preliminary data, based on a small sample, suggest that some patients with schizophrenia who are only partially responsive to standard neuroleptic treatment may benefit from the addition of triazolobenzodiazepines, such as alprazolam.

Original languageEnglish (US)
Pages (from-to)664-671
Number of pages8
JournalArchives of General Psychiatry
Volume45
Issue number7
DOIs
StatePublished - 1988
Externally publishedYes

Fingerprint

Alprazolam
Fluphenazine
Antipsychotic Agents
Homovanillic Acid
Schizophrenia
Therapeutics
Paranoid Disorders
Augmentation
Therapeutic Uses
Prefrontal Cortex
Psychotic Disorders
Atrophy
Hydrocortisone
Inpatients
Chronic Disease

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health

Cite this

Alprazolam Augmentation of the Antipsychotic Effects of Fluphenazine in Schizophrenic Patients : Preliminary Results. / Wolkowitz, Owen M.; Breier, Alan; Doran, Allen; Kelsoe, John; Lucas, Peter; Paul, Steven M.; Pickar, David.

In: Archives of General Psychiatry, Vol. 45, No. 7, 1988, p. 664-671.

Research output: Contribution to journalArticle

Wolkowitz, Owen M. ; Breier, Alan ; Doran, Allen ; Kelsoe, John ; Lucas, Peter ; Paul, Steven M. ; Pickar, David. / Alprazolam Augmentation of the Antipsychotic Effects of Fluphenazine in Schizophrenic Patients : Preliminary Results. In: Archives of General Psychiatry. 1988 ; Vol. 45, No. 7. pp. 664-671.
@article{3c7d4d12ec73443d875f7a49f3e5f779,
title = "Alprazolam Augmentation of the Antipsychotic Effects of Fluphenazine in Schizophrenic Patients: Preliminary Results",
abstract = "Alprazolam was added, under double-blind conditions, to stable fluphenazine hydrochloride regimens in 12 symptomatic, chronically ill inpatients with schizophrenia. The addition of alprazolam was associated with significant, albeit modest, reductions in global psychosis, thought disorder, and paranoia ratings, with a return to pretreatment levels on discontinuation of alprazolam treatment. Improvement in {"}negative symptoms{"} such as emotional withdrawal paralleled the changes in {"}positive symptoms{"} but did not, in itself, reach statistical significance. There were no significant changes in group mean plasma levels of homovanillic acid or 3-methoxy-4-hydroxyphenylglycol during alprazolam treatment, although group mean serum cortisol levels were significantly decreased by alprazolam treatment. Patients who responded favorably to alprazolam treatment were significantly more psychotic or anxious before treatment, were older, showed significant alprazolam-associated reductions in plasma levels of homovanillic acid, and had significantly more prominent prefrontal cortex atrophy on computed tomographic scans than patients in whom alprazolam was without therapeutic effect. These preliminary data, based on a small sample, suggest that some patients with schizophrenia who are only partially responsive to standard neuroleptic treatment may benefit from the addition of triazolobenzodiazepines, such as alprazolam.",
author = "Wolkowitz, {Owen M.} and Alan Breier and Allen Doran and John Kelsoe and Peter Lucas and Paul, {Steven M.} and David Pickar",
year = "1988",
doi = "10.1001/archpsyc.1988.01800310072009",
language = "English (US)",
volume = "45",
pages = "664--671",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "7",

}

TY - JOUR

T1 - Alprazolam Augmentation of the Antipsychotic Effects of Fluphenazine in Schizophrenic Patients

T2 - Preliminary Results

AU - Wolkowitz, Owen M.

AU - Breier, Alan

AU - Doran, Allen

AU - Kelsoe, John

AU - Lucas, Peter

AU - Paul, Steven M.

AU - Pickar, David

PY - 1988

Y1 - 1988

N2 - Alprazolam was added, under double-blind conditions, to stable fluphenazine hydrochloride regimens in 12 symptomatic, chronically ill inpatients with schizophrenia. The addition of alprazolam was associated with significant, albeit modest, reductions in global psychosis, thought disorder, and paranoia ratings, with a return to pretreatment levels on discontinuation of alprazolam treatment. Improvement in "negative symptoms" such as emotional withdrawal paralleled the changes in "positive symptoms" but did not, in itself, reach statistical significance. There were no significant changes in group mean plasma levels of homovanillic acid or 3-methoxy-4-hydroxyphenylglycol during alprazolam treatment, although group mean serum cortisol levels were significantly decreased by alprazolam treatment. Patients who responded favorably to alprazolam treatment were significantly more psychotic or anxious before treatment, were older, showed significant alprazolam-associated reductions in plasma levels of homovanillic acid, and had significantly more prominent prefrontal cortex atrophy on computed tomographic scans than patients in whom alprazolam was without therapeutic effect. These preliminary data, based on a small sample, suggest that some patients with schizophrenia who are only partially responsive to standard neuroleptic treatment may benefit from the addition of triazolobenzodiazepines, such as alprazolam.

AB - Alprazolam was added, under double-blind conditions, to stable fluphenazine hydrochloride regimens in 12 symptomatic, chronically ill inpatients with schizophrenia. The addition of alprazolam was associated with significant, albeit modest, reductions in global psychosis, thought disorder, and paranoia ratings, with a return to pretreatment levels on discontinuation of alprazolam treatment. Improvement in "negative symptoms" such as emotional withdrawal paralleled the changes in "positive symptoms" but did not, in itself, reach statistical significance. There were no significant changes in group mean plasma levels of homovanillic acid or 3-methoxy-4-hydroxyphenylglycol during alprazolam treatment, although group mean serum cortisol levels were significantly decreased by alprazolam treatment. Patients who responded favorably to alprazolam treatment were significantly more psychotic or anxious before treatment, were older, showed significant alprazolam-associated reductions in plasma levels of homovanillic acid, and had significantly more prominent prefrontal cortex atrophy on computed tomographic scans than patients in whom alprazolam was without therapeutic effect. These preliminary data, based on a small sample, suggest that some patients with schizophrenia who are only partially responsive to standard neuroleptic treatment may benefit from the addition of triazolobenzodiazepines, such as alprazolam.

UR - http://www.scopus.com/inward/record.url?scp=0023924694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023924694&partnerID=8YFLogxK

U2 - 10.1001/archpsyc.1988.01800310072009

DO - 10.1001/archpsyc.1988.01800310072009

M3 - Article

VL - 45

SP - 664

EP - 671

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 7

ER -